Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T

PARIS, May 11, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS – Euronext Growth: ALCLS), a clinical-stage biotechnological company employing its core proprietary technologies to develop best-in-class products based on gene-edited allogeneic CAR T-cells (“UCART”) in the field of immuno-oncology, and Sanofi (Euronext: SAN – NYSE: SNY), today entered into a partnership agreement and a supply agreement regarding alemtuzumab, an anti-CD52 monoclonal antibody, to be used as part of a lymphodepleting regimen in certain Cellectis sponsored UCART clinical trials.

See the original post here:
Cellectis and Sanofi partner on alemtuzumab as lymphodepletion agent for allogeneic CAR-T

Read more
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study

JENA, Germany, May 11, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today positive topline results from its U.S. Phase II IXPLORE study with vilobelimab in patients with anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated vasculitis, or AAV.

See more here:
InflaRx Announces Positive Topline Results for Vilobelimab from the U.S. Phase II ANCA-Associated Vasculitis IXPLORE Study

Read more
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2021 Financial Results

BASKING RIDGE, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2021.

More:
Timber Pharmaceuticals Provides Business Update and Announces First Quarter 2021 Financial Results

Read more
Innate Pharma Virtual 2021 Annual General Meeting

Marseille, France, May 12, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) has published the convening notice to the Bulletin des Annonces Légales Obligatoires for its Annual General Meeting of Shareholders (“AGM”), which will take place virtually at 11:00 a.m. CEST on May 28, 2021.

More here:
Innate Pharma Virtual 2021 Annual General Meeting

Read more
BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis

PARIS and CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- BIOPHYTIS SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“BIOPHYTIS” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it has recruited the 155th participant for Part 2 of its COVA Phase 2-3 study of Sarconeos (BIO101) in patients infected with COVID-19.

More:
BIOPHYTIS Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis

Read more
Burning Rock to be Added to MSCI China Index

GUANGZHOU, China, May 12, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will be included in the MSCI China Index, effective after the U.S. market close on May 27, 2021. Burning Rock is the only NGS-based precision oncology company from China that has been selected in the current MSCI semi-annual index review.

Read the rest here:
Burning Rock to be Added to MSCI China Index

Read more